DUBLIN, Ireland, Sept. 29, 2016 (GLOBE NEWSWIRE) -- Horizon Pharma plc (NASDAQ:HZNP), a biopharmaceutical company focused on improving patients’ lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, today announced that it has entered into a rebate agreement with Prime Therapeutics, which secures formulary status for its primary care medicines. The rebate agreement begins on October 1, 2016.
“Our philosophy is and will continue to be to ensure that patients have access to the medicines their physicians prescribe,” said Timothy P. Walbert, chairman, president and chief executive officer. “The Prime Therapeutics rebate agreement in addition to the previously announced CVS/Caremark agreement provides increased access to patients as well as sustainability and durability for our primary care business. We continue discussions and negotiations with other pharmacy benefit managers and payers with the goal of further increasing patient access for our clinically relevant primary care medicines.”
About Horizon Pharma plc
Horizon Pharma plc is a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. The Company markets nine medicines through its orphan, rheumatology and primary care business units. Horizon's global headquarters are in Dublin, Ireland. For more information, please visit www.horizonpharma.com. Follow @HZNPplc on Twitter or view careers on our LinkedIn page.
This report contains forward-looking statements, including, but not limited to, statements related to future formulary status with Prime Therapeutics and the timing thereof, and the impact of the rebate agreement with Prime Therapeutics. These forward-looking statements are based on information currently available to Horizon Pharma and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks that the rebate agreement could be terminated earlier than Horizon Pharma expects; whether healthcare plans contracting with Prime Therapeutics implement formulary restrictions that limit access to Horizon Pharma’s primary care medicines; whether rebate agreements will result in sustained durability for Horizon’s covered medicines in light of required rebate and administrative payments; whether Horizon Pharma will be able to enter into additional rebate agreements; and those risks detailed from time-to-time under the caption “Risk Factors” and elsewhere in Horizon Pharma’s filings and reports with the U.S. Securities and Exchange Commission. Horizon Pharma undertakes no duty or obligation to update any forward-looking statements contained in this report as a result of new information.
Contacts: Investors: John Thomas Executive Vice President, Strategy and Investor Relations Investorfirstname.lastname@example.org Tina Ventura Vice President, Investor Relations Investoremail@example.com U.S. Media: Geoff Curtis Senior Vice President, Corporate Communications firstname.lastname@example.org Ireland Media Contact: Ray Gordon Gordon MRM email@example.com
Source: Horizon Pharma plc